You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 27, 2024

Litigation Details for Par Pharmaceutical, Inc. v. Twi Pharmaceuticals, Inc. (Fed. Cir. 2014)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Par Pharmaceutical, Inc. v. Twi Pharmaceuticals, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Sign Up and ⤷  Sign Up .

Details for Par Pharmaceutical, Inc. v. Twi Pharmaceuticals, Inc. (Fed. Cir. 2014)

Date Filed Document No. Description Snippet Link To Document
2014-06-02 46 1996; 10:1657-1662. 6,375,986 B1 4/2002 Ryde eta!. … Pat. No. Pat. No. 6,028,065. 6,375,986 for "Solid Dose Nanoparticulate Compositions… Liversidge ’363 patent (1995) and EP ’215 patent (1994). The ’363 patent, A14876-86, is a continuation…alleging infringement of U.S. Patent 7,101,576 (“the ‘576 patent”). The patent relates to Par’s Megace ES…the claims of the ‘576 patent are enabled, or whether the patent claims patentable subject matter. External link to document
2014-08-19 65 Motion Filed the district court found that U.S. Patent 7,101,576 (the “’576 patent”) is invalid, ending over two years… ’576 patent were invalid as obvious. The entry of the final judgment rendered the ’576 patent invalid… its patent be held valid, Teva will be able to recover damages from respondents for past patent infringement…..................... 10, 13 In re Fenofibrate Patent Litigation, 972 F. Supp. 2d 655 (S.D.N.Y…brought suit against TWi for infringement of one patent under the Hatch-Waxman Act. A five-day trial was External link to document
2014-08-25 77 that the asserted claims of U.S. Patent No. 7,101,576 (“’576 patent”) would have been obvious. Par filed…..........................13 In re Fenofibrate Patent Litigation, 972 F. Supp. 2d 655 (S.D.N.Y…Court’s analysis of the likelihood of success in a patent appeal. See Revision Military, Inc. v. Balboa Mfg…success for certain injunctions when applied to a patent case). This Court has expressly adopted Hilton’… instead relies (at 15-16) on In re Fenofibrate Patent Litigation, 972 F. Supp. 2d 655, 657 (S.D.N.Y. External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.